NYT Hailed a $1.8B AI Telehealth Scam—Here’s the Damage

The New York Times didn’t just cover Medvi—the telehealth startup it described as a '$1.8 billion company' run by two brothers—it amplified a marketing narrative that smelled like a scam from the beginning. The article, published last week, framed Medvi’s AI-powered telehealth as a revolutionary force, complete with a valuation that would make most startups blush. Yet, as Techdirt’s breakdown reveals, not a single independent source corroborated the numbers, the team size, or the AI’s actual capabilities. Instead, the piece read like a press release dressed up as journalism, complete with the kind of breathless adjectives that usually accompany vaporware.

The real story wasn’t in the article but in the reactions it sparked. Friends, family, and even skeptical industry observers flooded inboxes with the same question: Is this real? That skepticism wasn’t just warranted—it was the only rational response. Medvi’s claims, from its valuation to its AI’s efficacy, lacked the kind of third-party validation that even mid-tier startups provide. The Times, however, treated it as gospel, turning what should have been a due diligence piece into a free promotional campaign.

This isn’t just a failure of journalism—it’s a case study in how easily AI hype can distort public perception. The damage isn’t just to Medvi’s credibility (if it ever had any) but to the broader telehealth sector, which now faces another round of questions about what’s real and what’s just another AI mirage.

The pattern here is alarmingly familiar. A flashy demo, a charismatic founder narrative, and just enough technical jargon to sound plausible—all delivered to a media ecosystem eager to declare the next big thing. The Times’ profile didn’t just miss the red flags; it ignored the most basic question any reporter should ask: Where’s the proof? No audit trail, no independent verification, no developer community signal—just a valuation pulled from thin air and a two-person team that somehow magically built a unicorn.

The broader implications are even more troubling. Every time a major outlet amplifies an unverified AI story, it erodes trust in legitimate innovations. Telehealth, a sector already struggling with regulatory scrutiny and skepticism about AI’s role, can’t afford this kind of PR disaster. The real winners here? The scammers who now know that with the right narrative, even the most reputable publications will play along.

For developers and engineers, this is a cautionary tale. The hype cycle rewards flashy demos and viral narratives, but the real work—building reliable, scalable, and verifiable systems—gets sidelined. Medvi’s story, if it’s true, is a reminder that AI’s biggest bottleneck isn’t technical but ethical: the willingness of institutions to hold companies accountable before declaring them the future.